Topic: Combining Locoregional and Systemic Therapies in Liver Cancer: From Strategy to Survival

The management of liver cancer has undergone profound changes with the development of systemic therapies such as targeted agents and immune checkpoint inhibitors, alongside significant advances in locoregional treatments, including ablation, transarterial chemoembolization (TACE), hepatic arterial infusion chemotherapy (HAIC), selective internal radiation therapy (SIRT), and radiotherapy. Emerging evidence suggests that combining locoregional and systemic therapies may achieve synergistic antitumor effects, prolong survival, and improve patient outcomes. Nevertheless, challenges remain in understanding the biological mechanisms underlying treatment synergy, optimizing combination strategies, and identifying predictive biomarkers. This Special Issue seeks to comprehensively explore the mechanistic rationale, clinical applications, treatment sequencing, and real-world experiences of combining locoregional and systemic therapies in liver cancer, with the goal of informing future therapeutic innovations and enhancing the multidisciplinary management of this complex disease.

Topics

1. Mechanistic Basis forCombining Locoregional and Systemic Therapies in Liver Cancer;

2. Immunomodulatory Effects of Locoregional Therapies in Liver CancerTreatment;

3. Optimization ofthe Timing and Sequencing of Locoregional and Systemic Therapies;

4. Clinical Evidence for TACE Plus Immune Checkpoint Inhibitors;

5. HAIC Combined with Targeted Therapies or Immunotherapies: Current Status and Future Directions;

6. Ablation and Immunotherapy: A New Paradigm forEarly-Stage Liver Cancer;

7. SIRTCombined with Systemic Therapies;

8. Radiotherapy Synergizing with Immune and Targeted Therapies in Liver Cancer;

9. Real-World Data and Challenges in Combined Locoregional-SystemicTreatmentStrategies;

10. Patient Selection Criteria for Combined Approaches in Intermediate-and Advanced-StageLiver Cancer;

11. Biomarkers Predicting Response to Locoregional-Systemic Combination Therapies;

12. Management of Adverse Events in Combined Locoregional and Systemic Treatments;

13. Future Directions: Emerging Agents and Innovative Combination Strategies;

14. Impact of Combined Therapies on Post-Treatment Liver Function and Long-Term Outcomes;

15. DesignofClinical Trials for Locoregional and Systemic Combination Therapies in Liver Cancer.